References
- Inman W HW, Vessey M P, Westerholm B. Thrombo-embolic disease and the steroid content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203–9
- Royal College of General Practitioners. Oral contraception and thromboembolic disease. J R Coll Gen Pract 1967; 13: 267–79
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–8
- Spitzer W O, Lewis M A, Heinemann L AJ, Thorogood M, MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders; an international multicenter case-control study. Lancet 1995; 346: 1572–82
- Jick H, Jick S S, Gurewich V, Myers M W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
- Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Duller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593–6
- Kluft C, Lansink M. Effects of oral contraceptives on hemostasis variables. Thromb Haemost 1997; 78: 315–26
- Koster T, Rosendaal F R, Reitsma P H, Van der Velden P A., Briët E, Vandenbroucke J P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A casecontrol study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study. Thromb Haemost 1994; 71: 719–22
- Jespersen J. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives—a short review. Eur J Contracept Reprod Health Care 1996; 1: 3–11
- Rosing J, Tans G, Nicolaes A E, Thomassen M CLGD, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997; 97: 233–8
- Vandenbroucke J P, Rosendaal F R. End of the line ‘third generation pill’ controversy. Lancet 1997; 349: 1113–14
- Farmer R DT, Lawrenson R A, Thomson C R, Kennedy J G, Hambleton I R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83–8
- Suissa S, Dlais L, Spitzer W O, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–6
- Lidegaard Ø, Edström B. Myocardial infarction, cerebral thrombosis and oral contraceptives. Two case control studies. Acta Obstet Cynecol Scand 1997; 76: 53
- Lewis M A, Heinemann L AJ, Spitzer W O, MacRae K D, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception 1997; 56: 129–40